{"id":16208,"date":"2019-07-08T08:33:03","date_gmt":"2019-07-08T06:33:03","guid":{"rendered":"https:\/\/news.embl.de\/?p=16208"},"modified":"2024-03-27T15:15:46","modified_gmt":"2024-03-27T14:15:46","slug":"twenty-years-of-emblem","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/","title":{"rendered":"Twenty years of EMBLEM"},"content":{"rendered":"

\u201cUltimately, what drives us is to make an impact on human health and to secure the best interests of EMBL,\u201d says G\u00e1bor Lamm, reflecting on the 20th anniversary of EMBLEM<\/a>, EMBL\u2019s technology transfer partner. EMBLEM was established in May 1999, and G\u00e1bor has been at the helm as Managing Director almost since its inception.<\/p>\n

Technology transfer is the bridge that takes innovative science from the lab and sees it through the process of development into commercial products \u2013 novel drugs, therapies, diagnostics and medical devices \u2013 that can be used for the benefit of society. It is one of EMBL\u2019s key missions.<\/p>\n

The decision to establish a company to handle technology transfer at EMBL was made in 1998. One of the reasons for this decision is that commercial activity would jeopardise EMBL\u2019s special status as an intergovernmental research organisation. EMBLEM was therefore set up as a company that operates according to German rather than international law, and which pays corporate tax in Germany. It is thus free to pursue commercial interests and to make decisions independently of EMBL.<\/p>\n

A close eye on science<\/h2>\n

That\u2019s not to say that there isn\u2019t a close relationship between EMBLEM and EMBL. On the contrary, G\u00e1bor and his team are proactive in identifying potential commercial opportunities. \u201cWe\u2019re at EMBL all the time,\u201d G\u00e1bor says. \u201cThe Faculty Seminars, where the different groups talk about their research, are very important for us, as are the faculty retreats. We interact with \u2013 and take good ideas from \u2013 people at all levels, from PhD students to senior scientists.\u201d<\/p>\n

Training scientists is also an important part of EMBLEM\u2019s work. All new PhD students receive training on various aspects of technology transfer, including patenting, public disclosure, and the various types of open-source licences.<\/p>\n

Securing EMBL\u2019s commercial interests<\/h2>\n

EMBLEM\u2019s technology transfer remit spans a broad spectrum of activities. These include identifying and protecting intellectual property, facilitating the establishment of spin-off companies from EMBL, licensing technologies to third parties, marketing and contracting scientific consultancy services, and developing collaborative research agreements.<\/p>\n

Collaborations are extremely valuable for EMBL scientists. \u201cIn the late 2000s we realised that just doing licence agreements was not enough,\u201d says G\u00e1bor. \u201cWith collaboration agreements, an industrial partner brings something to the table that\u2019s valuable for EMBL scientists, and the scientists contribute something that the industrial partner doesn\u2019t have. We have a joint collaboration on a focused project. It\u2019s a mutually beneficial arrangement.\u201d<\/p>\n

Two key questions<\/h2>\n

Every innovation is unique and presents its own distinct challenges. However, in all cases the team at EMBLEM ask two key questions at the outset. First, what is the fastest way to ensure that this technology is deployed in the market? And, second, what is the best way to ensure that this technology is made available as broadly as possible to benefit society?<\/p>\n

\u201cThe answers to both of those questions define everything else that we do,\u201d explains G\u00e1bor. \u201cThey define the intellectual property protection and commercialisation strategy: is the innovation going to be protected by a patent or by other means? If a patent, in which territories and with what scope? Is it going to be a single patent family, or do you build a patent portfolio around this topic? Who are the potential licensees? Will you put it into a start-up, or license it to an established company? Are you going to have multiple and exclusive licences? All of these decisions follow on from the answers to those two simple questions.\u201d<\/p>\n


\nEMBLEM helps us with technology transfer, licensing and contracts. We’re very lucky to have EMBLEM as part of EMBL, and it\u2019s just a pleasure working with our EMBLEM colleagues.<\/em>\n

Ewan Birney<\/b>
\nDirector of EMBL-EBI, Joint Head of Research and Senior Scientist
\n<\/p><\/div>\n

EMBL Ventures and the EMBL Technology Fund<\/h2>\n

From the start, G\u00e1bor was convinced of the importance of having a venture capital vehicle associated with EMBL. The EMBL Technology Fund, managed by EMBL Ventures<\/a>, was established to invest in life science start-ups emerging from EMBL and, importantly, from its member states. The first EMBL Technology Fund was raised in 2002. It amounted to \u20ac26 million, which was invested in 13 portfolio companies. Three of these originated at EMBL. The second fund, amounting to \u20ac40 million, was raised in 2011. It was invested in 11 portfolio companies, one of which was Luxendo (see below).<\/p>\n

In 2006, the EMBL Technology Development Fund was created. This is a classic \u2018proof-of-concept fund\u2019 to develop early inventions to a stage of commercial potential. The initial investment was about \u20ac1.7 million, which funded 11 proposals and resulted in four spin-off companies. These have already returned around \u20ac8 million to EMBL, attracted \u20ac24 million of additional external investment, and seen the creation of over 50 new jobs. By any measure, that is a good return on investment.<\/p>\n

Milestones on the road to success<\/h2>\n

EMBLEM is now among the top five technology transfer entities for the life sciences in continental Europe. In 2004, EMBLEM recouped all of EMBL\u2019s previous investments in technology transfer, and since then the company has returned an annual surplus to EMBL, amounting to over \u20ac40 million over the past 20 years. This money is earmarked for further collaborations between science and industry, across EMBL groups and sites. \u201cTo put this in context, it usually takes at least 10 years for a tech transfer company to break even,\u201d says G\u00e1bor. \u201cAnd many never make a cent.\u201d<\/p>\n

The company passed another significant milestone in 2018, when it generated in excess of \u20ac10 million from licensing, collaboration, service and consultancy contracts. \u201cThe monetary part of what we do is important, but by no means is it the main criterion when we make decisions,\u201d says G\u00e1bor. \u201cIf you only have the money in sight, you\u2019re going to lose the big picture. Our focus has always been the mid- and long-term sustainability of the activity, and to return value to EMBL and to society.\u201d<\/p>\n

The success of any company depends on the people behind it. At EMBLEM, a small team of highly trained scientists \u2013 many with postdoctoral research experience; most having also worked in industry \u2013 are driven by a passion for science and a desire to make a positive impact. \u201cWe are innovators, bridge-builders and service providers,\u201d says G\u00e1bor. \u201cWe don\u2019t sit around and wait for things to happen.\u201d<\/p>\n

\n

“EMBLEM is committed to bringing together researchers from academia and industry. My research has benefited from a decade of their excellent support, and I look forward to working with them in the future.<\/em>”<\/p>\n

Lars Steinmetz<\/strong>
\nSenior Scientist and Director of the Stanford | EMBL Life Science Alliance<\/p>\n

<\/p><\/div>\n

Looking to the future<\/h2>\n

EMBLEM\u2019s many successes over the past 20 years are cause for pride and celebration, but there is no room for complacency. G\u00e1bor Lamm is looking to the future. \u201cWe want to maintain a high level of service for EMBL, and to expand our business offerings. We\u2019d also like to develop new initiatives to foster innovation, and to develop commercially viable opportunities. We want to help deepen EMBL\u2019s relationships with industry, and to support the institute in achieving its goals.\u201d With quiet confidence he concludes, \u201cWe\u2019re good at what we do.\u201d This is surely an understatement, but the results speak for themselves, without any need for embellishment.<\/p>\n

\"EMBLEM<\/a>
IMAGE: Holly Joynes\/EMBL.<\/figcaption><\/figure>\n

Spotlight on Luxendo<\/h1>\n

\u201cIt was obvious that this technology was a breakthrough,\u201d says EMBL group leader Lars Hufnagel, of the light-sheet microscopes developed in his lab at EMBL. The MuVi SPIM (multi-view single-plane illumination microscope) and InVi SPIM (inverted view SPIM), developed in collaboration with EMBL group leader Jan Ellenberg, sparked intense interest in the scientific community. Inundated with requests from scientists who wanted to come to EMBL to use the technology, or acquire it themselves, Hufnagel realised he needed to get the technology into the market. Fast.<\/p>\n

Hufnagel and Ellenberg were building on the work of Ernst Stelzer, the former EMBL group leader who developed the first generation of SPIM microscopes at EMBL, and filed the first patent on the technology in 2002. \u201cWhat was missing in the early prototypes was usability by biologists,\u201d says J\u00fcrgen Bauer, EMBLEM\u2019s Deputy Managing Director. \u201cWhen Lars brought the technology to the next level of development, and generated instruments that were more robust and usable \u2013 closer to a product \u2013 we agreed that this would be a perfect basis to turn this into a spin-off company.\u201d<\/p>\n

Mutual benefits<\/h2>\n

The resulting company \u2013 Luxendo<\/a> \u2013 was created in September 2015 and venture capital funded by both the EMBL Technology Fund, managed by EMBL Ventures, and Life Sciences Partners<\/a>, one of the largest life science venture investors in Europe, based in Amsterdam. Luxendo was acquired by the global scientific instrument manufacturer Bruker after only a year and a half. \u201cBruker recognised that we had a good team, and they kept it and expanded it,\u201d says Hufnagel. Luxendo continues to be hosted on the EMBL campus in Heidelberg. \u201cInitially there was a lot of knowledge from my lab going into this company,\u201d says Hufnagel. \u201cBut now Luxendo finds better solutions, builds better components, which we integrate. That knowledge now flows back to EMBL.\u201d<\/p>\n

The Luxendo story exemplifies the unique ecosystem at EMBL<\/p><\/blockquote>\n

\u201cThis is a great example of excellent science coming together with perfect engineering competence to build a solution for scientists to answer biological questions,\u201d says Bauer. \u201cThe Luxendo story exemplifies the unique ecosystem at EMBL which, together with EMBLEM and EMBL Ventures, allows innovations to be fast-tracked to prototype stage and then spun out into a start-up, which makes EMBL technology rapidly available to the scientific community and commercial partners.\u201d<\/p>\n

\"Microscopy
This MuVi SPIM image reveals a fruit fly larva\u2019s developing tracheal system \u2013 the network of tubes that transports oxygen and other gases around the fly\u2019s body. IMAGE: Dimitri Kromm, Hufnagel group; Daniel Rios, Leptin group\/EMBL<\/figcaption><\/figure>\n

Open Targets: a paradigm for collaboration<\/h1>\n

\u201cThis is collaboration at its best,\u201d Birgit Kerber, Business Development Manager at EMBLEM, says of Open Targets<\/a>. \u201cIt\u2019s a\u00a0role model for large public\u2013private partnerships and exemplifies how EMBL and EMBLEM together are successfully interacting with industry.\u201d<\/p>\n

\"Open
Open Targets seeks to develop innovative approaches to drug target identification. IMAGE: Spencer Phillips\/EMBL<\/figcaption><\/figure>\n

Open Targets was established in 2014 and is based at the Wellcome Genome Campus<\/a> in Cambridge, UK. It brings together partners from academia and industry to develop innovative approaches to drug target identification and prioritisation, using human genetics, genomics and other omics data. There are currently five pharma and two academic partners, one of which is EMBL\u2019s European Bioinformatics Institute<\/a> (EMBL-EBI), whose world-leading competencies are essential to Open Targets.<\/p>\n

\u201cThere\u2019s nothing going on in the life sciences, either in the research space or the development space, that is not impacted by bioinformatics,\u201d says EMBL-EBI Director Rolf Apweiler, \u201cand we have the expertise in large-scale data analysis and provision of these services to the scientific community.\u201d<\/p>\n

Shoulder to shoulder<\/h2>\n

EMBLEM is responsible for the business development side of Open Targets, and Kerber plays a lead role in getting new industry partners involved. \u201cOpen Targets works extremely well. It has established a portfolio of more than 50 interlinked projects and has published more than 20 articles across three therapeutic areas: oncology, immunology and neurodegenerative disease,\u201d she says. \u201cScientists from academia and industry are working shoulder to shoulder on these projects. It\u2019s a very intense collaboration, and that\u2019s why it\u2019s so successful. We\u2019re operating in what\u2019s called the pre-competitive space, where there\u2019s room to share information, and that is beneficial to everybody.\u201d<\/p>\n

It’s a very intense collaboration, and that’s why it’s so successful<\/p><\/blockquote>\n

Open Targets hit the headlines earlier this year, with the announcement that researchers had identified thousands of genes that are key to cancer survival. The unique collaborative framework of Open Targets generates important results like these, and helps to facilitate and accelerate their translation into the development of new, safe and efficacious drugs.<\/p>\n

Kerber is focused on the future. \u201cExpanding the breadth of Open Targets, and having more Open Targets-like initiatives in other spaces \u2013 that\u2019s a good prospect,\u201d she says. \u201cIt\u2019s a visionary initiative.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Reflecting on 20 years of EMBLEM<\/p>\n","protected":false},"author":68,"featured_media":67489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[866,865,303,868,763,869,238],"embl_taxonomy":[],"class_list":["post-16208","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lab-matters","tag-embl-technology-fund","tag-embl-ventures","tag-emblem","tag-luxendo","tag-open-targets","tag-patent","tag-technology-transfer"],"acf":{"article_intro":"

Reflecting on the past and looking to the future of technology transfer at EMBL<\/p>\n","related_links":false,"featured":true,"show_featured_image":false,"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"source_article":false,"in_this_article":false,"press_contact":"None","article_translations":false,"languages":""},"embl_taxonomy_terms":[],"yoast_head":"\nTwenty years of EMBLEM | EMBL<\/title>\n<meta name=\"description\" content=\"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Twenty years of EMBLEM | EMBL\" \/>\n<meta property=\"og:description\" content=\"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-08T06:33:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-27T14:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Cella Carr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cella Carr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\"},\"author\":{\"name\":\"Cella Carr\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/3bb76de286246270a71cf08b368e0594\"},\"headline\":\"Twenty years of EMBLEM\",\"datePublished\":\"2019-07-08T06:33:03+00:00\",\"dateModified\":\"2024-03-27T14:15:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\"},\"wordCount\":2048,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg\",\"keywords\":[\"embl technology fund\",\"embl ventures\",\"emblem\",\"luxendo\",\"open targets\",\"patent\",\"technology transfer\"],\"articleSection\":[\"Lab Matters\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\",\"name\":\"Twenty years of EMBLEM | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg\",\"datePublished\":\"2019-07-08T06:33:03+00:00\",\"dateModified\":\"2024-03-27T14:15:46+00:00\",\"description\":\"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg\",\"width\":1000,\"height\":600,\"caption\":\"The EMBLEM team: (left to right) J\u00fcrgen Bauer, Yvonne Meyer, Birgit Kerber, Annabelle Grimm, G\u00e1bor Lamm, Christina B\u00f6hm, Thorsten Schneider and Ilka Singer. PHOTO: Marietta Schupp\/EMBL\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/3bb76de286246270a71cf08b368e0594\",\"name\":\"Cella Carr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0c018afa51082d626819d9140ccdc9c99bbbfdd79750cf4223c486ea8305e60e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0c018afa51082d626819d9140ccdc9c99bbbfdd79750cf4223c486ea8305e60e?s=96&d=mm&r=g\",\"caption\":\"Cella Carr\"},\"description\":\"Cella is a writer and editor. As Editorial Officer in the Communications team she spent her days chatting to smart people about science, and writing their stories for EMBLetc. Red hair is the source of her superpowers (this has yet to be proven by science).\",\"url\":\"https:\/\/www.embl.org\/news\/author\/cella-carr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Twenty years of EMBLEM | EMBL","description":"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/","og_locale":"en_US","og_type":"article","og_title":"Twenty years of EMBLEM | EMBL","og_description":"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2019-07-08T06:33:03+00:00","article_modified_time":"2024-03-27T14:15:46+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","type":"image\/jpeg"}],"author":"Cella Carr","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Cella Carr","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/"},"author":{"name":"Cella Carr","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/3bb76de286246270a71cf08b368e0594"},"headline":"Twenty years of EMBLEM","datePublished":"2019-07-08T06:33:03+00:00","dateModified":"2024-03-27T14:15:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/"},"wordCount":2048,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","keywords":["embl technology fund","embl ventures","emblem","luxendo","open targets","patent","technology transfer"],"articleSection":["Lab Matters"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/","name":"Twenty years of EMBLEM | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","datePublished":"2019-07-08T06:33:03+00:00","dateModified":"2024-03-27T14:15:46+00:00","description":"EMBLEM, EMBL's technology transfer partner, marks its twentieth anniversary in 2019. We reflect on the company's many successes to date.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/twenty-years-of-emblem\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","width":1000,"height":600,"caption":"The EMBLEM team: (left to right) J\u00fcrgen Bauer, Yvonne Meyer, Birgit Kerber, Annabelle Grimm, G\u00e1bor Lamm, Christina B\u00f6hm, Thorsten Schneider and Ilka Singer. PHOTO: Marietta Schupp\/EMBL"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/3bb76de286246270a71cf08b368e0594","name":"Cella Carr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0c018afa51082d626819d9140ccdc9c99bbbfdd79750cf4223c486ea8305e60e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0c018afa51082d626819d9140ccdc9c99bbbfdd79750cf4223c486ea8305e60e?s=96&d=mm&r=g","caption":"Cella Carr"},"description":"Cella is a writer and editor. As Editorial Officer in the Communications team she spent her days chatting to smart people about science, and writing their stories for EMBLetc. Red hair is the source of her superpowers (this has yet to be proven by science).","url":"https:\/\/www.embl.org\/news\/author\/cella-carr\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2019\/07\/EMBLEM-team-cropped-1.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/16208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/68"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=16208"}],"version-history":[{"count":29,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/16208\/revisions"}],"predecessor-version":[{"id":67509,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/16208\/revisions\/67509"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/67489"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=16208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=16208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=16208"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=16208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}